secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001193125-24-137731
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics: Phase 2a trial of bexotegrast shows reduced lung collagen and improved lung function in IPF
--------------------------------------------------------------------------------

- Bexotegrast 160 mg reduced total lung collagen on PET imaging vs. increased collagen on placebo over 12 weeks.
- Treated patients showed improvements in forced vital capacity (FVC) and cough severity at all timepoints vs. placebo.
- No drug-related serious adverse events or discontinuations reported; most TEAEs mild.
- Trial enrolled 10 patients (7 active, 3 placebo); 8 on standard of care (mostly nintedanib).
- Biomarkers integrin beta-6 and PRO-C3 reduced in bexotegrast arm vs. placebo at weeks 4 and 12.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000119312524137731/0001193125-24-137731-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000119312524137731/d798874d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-137731

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer